MA46230B1 - Mutations de protéine d'enveloppe du vih stabilisant la forme trimère - Google Patents
Mutations de protéine d'enveloppe du vih stabilisant la forme trimèreInfo
- Publication number
- MA46230B1 MA46230B1 MA46230A MA46230A MA46230B1 MA 46230 B1 MA46230 B1 MA 46230B1 MA 46230 A MA46230 A MA 46230A MA 46230 A MA46230 A MA 46230A MA 46230 B1 MA46230 B1 MA 46230B1
- Authority
- MA
- Morocco
- Prior art keywords
- hiv
- envelope protein
- envelope proteins
- hiv envelope
- trimeric form
- Prior art date
Links
- 101710091045 Envelope protein Proteins 0.000 title abstract 9
- 101710188315 Protein X Proteins 0.000 title abstract 9
- 102100021696 Syncytin-1 Human genes 0.000 title abstract 9
- 230000035772 mutation Effects 0.000 title abstract 2
- 230000000087 stabilizing effect Effects 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 239000013638 trimer Substances 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne des protéines d'enveloppe du virus de l'immunodéficience humaine (vih) présentant des mutations qui stabilisent la forme trimère de la protéine d'enveloppe. Les protéines d'enveloppe du vih présentent certaines substitutions d'acides aminés à des positions particulières dans la séquence de protéine d'enveloppe. Les protéines d'enveloppe du vih décrites dans la description présentent un pourcentage amélioré de formation de trimère et/ou un rendement amélioré en trimère telles que comparées à une protéine d'enveloppe du vih qui ne possède pas l'une ou plusieurs des substitutions d'acides aminés indiquées. La présente invention concerne également des molécules d'acide nucléique et des vecteurs codant pour les protéines d'enveloppe du vih, ainsi que des compositions contenant les protéines d'enveloppe du vih, l'acide nucléique, et les vecteurs.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16188866 | 2016-09-15 | ||
| PCT/EP2017/073141 WO2018050747A1 (fr) | 2016-09-15 | 2017-09-14 | Mutations de protéine d'enveloppe du vih stabilisant la forme trimère |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46230A MA46230A (fr) | 2019-07-24 |
| MA46230B1 true MA46230B1 (fr) | 2020-10-28 |
Family
ID=57017955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46230A MA46230B1 (fr) | 2016-09-15 | 2017-09-14 | Mutations de protéine d'enveloppe du vih stabilisant la forme trimère |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10793607B2 (fr) |
| EP (2) | EP3512543B1 (fr) |
| JP (2) | JP7178344B2 (fr) |
| KR (1) | KR102513146B1 (fr) |
| CN (1) | CN109689091A (fr) |
| AR (1) | AR109528A1 (fr) |
| AU (2) | AU2017327672B2 (fr) |
| BR (1) | BR112019004593A2 (fr) |
| CA (1) | CA3036959A1 (fr) |
| CY (1) | CY1124518T1 (fr) |
| DK (1) | DK3512543T3 (fr) |
| EA (1) | EA201990715A1 (fr) |
| ES (1) | ES2824525T3 (fr) |
| HR (1) | HRP20201458T1 (fr) |
| HU (1) | HUE052008T2 (fr) |
| IL (2) | IL265186B (fr) |
| LT (1) | LT3512543T (fr) |
| MA (1) | MA46230B1 (fr) |
| MD (1) | MD3512543T2 (fr) |
| MX (1) | MX2019002938A (fr) |
| MY (1) | MY190534A (fr) |
| PH (1) | PH12019500280A1 (fr) |
| PL (1) | PL3512543T3 (fr) |
| PT (1) | PT3512543T (fr) |
| RS (1) | RS60919B1 (fr) |
| SG (2) | SG11201901206SA (fr) |
| SI (1) | SI3512543T1 (fr) |
| SM (1) | SMT202000548T1 (fr) |
| TW (1) | TWI742158B (fr) |
| WO (1) | WO2018050747A1 (fr) |
| ZA (1) | ZA201901597B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3964569A1 (fr) | 2015-12-15 | 2022-03-09 | Janssen Vaccines & Prevention B.V. | Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation |
| US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| WO2017152146A2 (fr) | 2016-03-03 | 2017-09-08 | Duke University | Compositions et procédés pour induire des anticorps du vih-1 |
| BR112018072248A2 (pt) * | 2016-05-02 | 2019-02-12 | The Scripps Research Institute | composições e métodos relacionados a imunógenos contra hiv-1 |
| KR102389489B1 (ko) | 2016-06-16 | 2022-04-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 백신 제형 |
| CA3035759A1 (fr) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Procedes pour induire une reponse immunitaire contre une infection par le virus de l'immunodeficience humaine chez des sujets subissant un traitement antiretroviral |
| SG11201901206SA (en) | 2016-09-15 | 2019-04-29 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| EP3519428A4 (fr) | 2016-10-03 | 2020-07-08 | Duke University | Procédés d'identification d'immunogènes par ciblage de mutations improbables |
| WO2018229711A1 (fr) | 2017-06-15 | 2018-12-20 | Janssen Vaccines & Prevention B.V. | Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation |
| WO2019016062A1 (fr) | 2017-07-19 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | Mutations de protéine d'enveloppe du vih stabilisant la forme trimère |
| AU2019285048B2 (en) | 2018-06-13 | 2023-06-08 | The Scripps Research Institute | Nanoparticle vaccines with novel structural components |
| EA038287B1 (ru) * | 2018-06-18 | 2021-08-04 | Янссен Вэксинс Энд Превеншн Б.В. | Стабилизирующие тример мутации белка оболочки hiv |
| EP3860650A4 (fr) | 2018-10-01 | 2022-06-29 | Duke University | Mutations stabilisant l'enveloppe du vih-1 |
| AU2020211990A1 (en) * | 2019-01-22 | 2021-08-12 | 2Seventy Bio, Inc. | Methods and systems for manufacturing viral vectors |
| CN110184298B (zh) * | 2019-05-15 | 2023-05-16 | 武汉璟泓科技股份有限公司 | Hiv突变型表面糖蛋白及其纳米化抗原与制备方法 |
| WO2021097254A1 (fr) * | 2019-11-14 | 2021-05-20 | Emory University | Immunogènes du vih, vaccins et procédés associés |
| WO2022100703A1 (fr) * | 2020-11-12 | 2022-05-19 | 厦门大学 | Protéine membranaire modifiée du virus de l'immunodéficience humaine et son utilisation |
| WO2022180007A1 (fr) | 2021-02-23 | 2022-09-01 | Janssen Vaccines & Prevention B.V. | Mutation de protéine d'enveloppe du vih stabilisant un trimère |
| WO2023156505A1 (fr) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimère stabilisant les mutations de protéines d'enveloppe du vih r304v, n302m et t320l |
| US20250197455A1 (en) * | 2022-03-27 | 2025-06-19 | TThe United States of America, as represented by the Secretary, Department of Health and Human Servi | Base-covered hiv-1 envelope ectodomains and their use |
| EP4608843A1 (fr) * | 2022-10-24 | 2025-09-03 | Duke University | Stabilisation d'enveloppes du virus de l'immunodéficience humaine (vih) |
| CN118515733B (zh) * | 2023-02-20 | 2025-11-18 | 菲鹏生物股份有限公司 | Hiv蛋白及其在检测hiv抗体中的应用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| CA1341245C (fr) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Virus recombinant de la vaccine derive du virus modifie ankara |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
| US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| CA2384271A1 (fr) | 1999-09-17 | 2001-03-22 | Joseph G. Sodroski | Trimeres stabilises solubles de glycoproteines |
| CN101676389A (zh) | 2000-11-23 | 2010-03-24 | 巴法里安诺迪克有限公司 | 改良安卡拉痘苗病毒变体 |
| CN102409063A (zh) | 2001-12-04 | 2012-04-11 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
| MXPA04008891A (es) | 2002-04-25 | 2004-11-26 | Crucell Holland Bv | Medios y metodos para la produccion de vectores de adenovirus. |
| AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| EP1578766B1 (fr) | 2002-12-03 | 2013-02-13 | University of Massachusetts | Vaccins polyvalents a adn contre la glycoproteine du hiv-1 primaire et procedes de vaccination |
| AU2004226345B2 (en) | 2003-03-28 | 2011-12-22 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | MVA virus expressing modified HIV envelope, gag, and pol genes |
| US20070166784A1 (en) | 2003-09-15 | 2007-07-19 | Barnett Susan W | Combination approaches for generating immune responses |
| CA2918585C (fr) * | 2003-09-17 | 2019-05-21 | Duke University | Immunogenes consensus/ancestraux |
| US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
| WO2006002079A2 (fr) | 2004-06-15 | 2006-01-05 | Progenics Pharmaceuticals, Inc. | Anticorps de neutralisation du vih-1 elicites par un complexe trimerique de glycoproteines d'enveloppe du vih-1 |
| BRPI0513390A (pt) | 2004-07-16 | 2008-05-06 | Us Gov Health & Human Serv | vacinas contra aids contendo construções de ácido nucléico cmv/r |
| AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
| CN1857345B (zh) * | 2005-05-08 | 2010-09-01 | 谢秀琼 | 一种治疗偏头痛的药物组合物及其制备方法 |
| CA2656741A1 (fr) | 2005-07-06 | 2007-01-11 | University Of Maryland Biotechnology Institute | Immunogene a base d'enveloppe de vih de type limite presentant simultanement des sites de liaison de recepteur et de co-recepteur |
| CA2620874A1 (fr) | 2005-08-23 | 2007-03-01 | The Regents Of The University Of California | Vaccin polyvalent |
| WO2007104792A2 (fr) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci |
| US20110076298A1 (en) | 2006-06-19 | 2011-03-31 | Olson William C | Soluble stabilized trimeric hiv env proteins and uses thereof |
| EP2073840A4 (fr) | 2006-10-23 | 2010-10-27 | Progenics Pharm Inc | Polypeptides d'enveloppe gp140 modifiés en provenance d'isolats du vih-1, compositions, complexes trimériques et utilisations de ceux-ci |
| WO2008140579A2 (fr) | 2006-11-17 | 2008-11-20 | New York University | Induction d'anticorps neutralisants largement réactifs par la concentration de la réponse immunitaire sur les épitopes v3 de l'enveloppe gp120 du vih-1 |
| CN101675068A (zh) | 2007-03-02 | 2010-03-17 | 葛兰素史密丝克莱恩生物有限公司 | 新的方法和组合物 |
| SMT202000101T1 (it) | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| SMT201800631T1 (it) | 2008-11-18 | 2019-01-11 | Beth Israel Deaconess Medical Ct Inc | Vaccini antivirali con immunogenicità cellulare migliorata |
| WO2010096561A1 (fr) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Protéines gag du vih/vis de synthèse et leurs utilisations |
| US9241986B2 (en) | 2010-01-04 | 2016-01-26 | Kj Biosciences Llc | DPS fusion proteins for use in vaccines and diagnostics |
| DK2529010T3 (en) | 2010-01-28 | 2017-07-24 | Bavarian Nordic As | MUTANTS OF VACCINIAVIRUS CONTAINING THE MAIN GENOMIC DELETIONS OF VAT |
| AU2011296065B2 (en) | 2010-08-31 | 2016-01-28 | International Aids Vaccine Initiative | Human immunodeficiency virus (HIV)-neutralizing antibodies |
| US20140348791A1 (en) | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| CA2789539A1 (fr) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection de virus de la stomatite vesiculeuse recombinant exprimant des proteines hiv-1 en neutralisant largement les anticorps |
| WO2013055908A1 (fr) | 2011-10-12 | 2013-04-18 | The Scripps Research Institute | Mini boucle v3 de gp120 du vih-1 et ses utilisations |
| US9683268B2 (en) | 2012-09-19 | 2017-06-20 | Beth Israel Deaconess | Viruses associated with immunodeficiency and enteropathy and methods using same |
| CA2891349C (fr) | 2012-11-16 | 2023-07-18 | Beth Israel Deaconess Medical Center, Inc. | Adenovirus recombinants et leur utilisation |
| AP2015008634A0 (en) | 2013-01-07 | 2015-07-31 | Beth Israel Hospital | Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same |
| WO2014124301A1 (fr) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Nanostructures protéiques à auto-assemblage |
| US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
| WO2016037154A1 (fr) * | 2014-09-04 | 2016-03-10 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Protéines de l'enveloppe du vih-1 recombinantes et leur utilisation |
| MY175620A (en) | 2014-09-26 | 2020-07-02 | Beth Israel Deaconess Medical Ct Inc | Methods and compositions for inducing protective immunity against human immunodeficiency virus infection |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| ES2836432T3 (es) | 2015-03-18 | 2021-06-25 | Janssen Vaccines & Prevention Bv | Ensayos para sistemas de expresión recombinante |
| EP3964569A1 (fr) | 2015-12-15 | 2022-03-09 | Janssen Vaccines & Prevention B.V. | Antigènes, vecteurs, compositions du virus de l'immunodéficience humaine et leurs procédés d'utilisation |
| KR102389489B1 (ko) | 2016-06-16 | 2022-04-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 백신 제형 |
| CA3035759A1 (fr) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Procedes pour induire une reponse immunitaire contre une infection par le virus de l'immunodeficience humaine chez des sujets subissant un traitement antiretroviral |
| SG11201901206SA (en) * | 2016-09-15 | 2019-04-29 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| WO2019016062A1 (fr) * | 2017-07-19 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | Mutations de protéine d'enveloppe du vih stabilisant la forme trimère |
-
2017
- 2017-09-14 SG SG11201901206SA patent/SG11201901206SA/en unknown
- 2017-09-14 LT LTEP17769027.8T patent/LT3512543T/lt unknown
- 2017-09-14 SM SM20200548T patent/SMT202000548T1/it unknown
- 2017-09-14 PT PT177690278T patent/PT3512543T/pt unknown
- 2017-09-14 JP JP2019514316A patent/JP7178344B2/ja active Active
- 2017-09-14 MY MYPI2019001242A patent/MY190534A/en unknown
- 2017-09-14 MD MDE20190798T patent/MD3512543T2/ro unknown
- 2017-09-14 KR KR1020197007592A patent/KR102513146B1/ko active Active
- 2017-09-14 SG SG10202001956UA patent/SG10202001956UA/en unknown
- 2017-09-14 EP EP17769027.8A patent/EP3512543B1/fr active Active
- 2017-09-14 BR BR112019004593-7A patent/BR112019004593A2/pt not_active IP Right Cessation
- 2017-09-14 HU HUE17769027A patent/HUE052008T2/hu unknown
- 2017-09-14 US US15/704,651 patent/US10793607B2/en not_active Expired - Fee Related
- 2017-09-14 MX MX2019002938A patent/MX2019002938A/es unknown
- 2017-09-14 CN CN201780054555.6A patent/CN109689091A/zh active Pending
- 2017-09-14 ES ES17769027T patent/ES2824525T3/es active Active
- 2017-09-14 HR HRP20201458TT patent/HRP20201458T1/hr unknown
- 2017-09-14 EA EA201990715A patent/EA201990715A1/ru unknown
- 2017-09-14 EP EP20179463.3A patent/EP3747463A1/fr not_active Withdrawn
- 2017-09-14 RS RS20201208A patent/RS60919B1/sr unknown
- 2017-09-14 WO PCT/EP2017/073141 patent/WO2018050747A1/fr not_active Ceased
- 2017-09-14 MA MA46230A patent/MA46230B1/fr unknown
- 2017-09-14 AU AU2017327672A patent/AU2017327672B2/en not_active Ceased
- 2017-09-14 SI SI201730416T patent/SI3512543T1/sl unknown
- 2017-09-14 IL IL265186A patent/IL265186B/en unknown
- 2017-09-14 AR ARP170102536A patent/AR109528A1/es not_active Application Discontinuation
- 2017-09-14 DK DK17769027.8T patent/DK3512543T3/da active
- 2017-09-14 PL PL17769027T patent/PL3512543T3/pl unknown
- 2017-09-14 CA CA3036959A patent/CA3036959A1/fr active Pending
- 2017-09-14 IL IL294832A patent/IL294832A/en unknown
- 2017-09-15 TW TW106131855A patent/TWI742158B/zh not_active IP Right Cessation
-
2019
- 2019-02-08 PH PH12019500280A patent/PH12019500280A1/en unknown
- 2019-03-14 ZA ZA2019/01597A patent/ZA201901597B/en unknown
-
2020
- 2020-08-13 US US16/947,694 patent/US11365222B2/en active Active
- 2020-10-09 CY CY20201100952T patent/CY1124518T1/el unknown
- 2020-11-13 AU AU2020267278A patent/AU2020267278B2/en not_active Expired - Fee Related
-
2022
- 2022-06-08 US US17/805,873 patent/US11820796B2/en active Active
- 2022-11-14 JP JP2022181566A patent/JP2023011941A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46230A (fr) | Mutations de protéine d'enveloppe du vih stabilisant la forme trimère | |
| CL2021002742A1 (es) | Una proteína crispr de prevotella y francisella 1 (cpf1) aislada de francisella tularensis; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004) | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| MX389173B (es) | Receptores de celulas t. | |
| EP4442816A3 (fr) | Glycoprotéine mutée du virus de la stomatite vésiculaire | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| MA41879A1 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers | |
| MX395611B (es) | Receptores de celulas t. | |
| TNSN08064A1 (en) | Albumin fusion proteins | |
| RU2018122823A (ru) | Мутанты белка f rsv | |
| PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
| MA37471A1 (fr) | Formulation lyophilise et aqueuse d’anticorps anti-cd40 | |
| MX2022013945A (es) | Nuevas proteinas de union a repeticiones de anquirina y sus usos. | |
| SI3191511T1 (en) | Improved TNF binders | |
| MX2023011629A (es) | Proteinas piv3 f prefusion estabilizadas. | |
| EA202092464A1 (ru) | Способы получения стабильных композиций на основе белков | |
| MA56142A1 (fr) | Protéine modifiée séparée vp1 de capside de aav5 | |
| EA202191208A1 (ru) | ВЕКТОРЫ, СОДЕРЖАЩИЕ AIMP2-DX2 И ЦЕЛЕВЫЕ НУКЛЕИНОВЫЕ КИСЛОТЫ ДЛЯ miR-142, И ИХ ПРИМЕНЕНИЕ | |
| EA202191123A1 (ru) | Миниатюризированные дистрофины и их применения | |
| PH12022550238A1 (en) | Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations | |
| Martellini et al. | HIV-1 enhancing effect of prostatic acid phosphatase peptides is reduced in human seminal plasma | |
| MX2023009835A (es) | Mutacion estabilizante de trimero de proteina de envoltura del vih. | |
| EA202092229A1 (ru) | Мутеины cd4 и способы их применения | |
| EA201890187A1 (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
| PH12022553417A1 (en) | Stabilized corona virus spike protein fusion proteins |